RHO and cardiovascular disorder: In one study, DL0805 has been shown to be a possible therapeutic agent in cardiovascular disease by acting as a vasorelaxant in rat thoracic aortas through inhibition of the Rho/ROCK signaling pathway.227 RhoA is required for the phosphorylation of myosin light chain, a key event in the regulation of vascular smooth muscle cell contraction.